JP2016519107A5 - - Google Patents

Download PDF

Info

Publication number
JP2016519107A5
JP2016519107A5 JP2016507634A JP2016507634A JP2016519107A5 JP 2016519107 A5 JP2016519107 A5 JP 2016519107A5 JP 2016507634 A JP2016507634 A JP 2016507634A JP 2016507634 A JP2016507634 A JP 2016507634A JP 2016519107 A5 JP2016519107 A5 JP 2016519107A5
Authority
JP
Japan
Prior art keywords
hypoxia
predetermined value
cancer
degree
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016507634A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016519107A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/033491 external-priority patent/WO2014169035A1/en
Publication of JP2016519107A publication Critical patent/JP2016519107A/ja
Publication of JP2016519107A5 publication Critical patent/JP2016519107A5/ja
Pending legal-status Critical Current

Links

JP2016507634A 2013-04-10 2014-04-09 Th−302抗癌療法のための予測および応答のバイオマーカー Pending JP2016519107A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361810643P 2013-04-10 2013-04-10
US61/810,643 2013-04-10
PCT/US2014/033491 WO2014169035A1 (en) 2013-04-10 2014-04-09 Predictive and response biomarker for th-302 anti-cancer therapy

Publications (2)

Publication Number Publication Date
JP2016519107A JP2016519107A (ja) 2016-06-30
JP2016519107A5 true JP2016519107A5 (enExample) 2017-06-01

Family

ID=51689977

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016507634A Pending JP2016519107A (ja) 2013-04-10 2014-04-09 Th−302抗癌療法のための予測および応答のバイオマーカー

Country Status (4)

Country Link
US (1) US20160296538A1 (enExample)
EP (1) EP2983591A4 (enExample)
JP (1) JP2016519107A (enExample)
WO (1) WO2014169035A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10071109B2 (en) 2013-11-06 2018-09-11 Molecular Templates, Inc. Predictive biomarker for hypoxia-activated prodrug therapy
EP3226869A4 (en) 2014-12-03 2018-07-18 Auckland UniServices, Ltd. Kinase inhibitor prodrug for the treatment of cancer
US11504075B2 (en) * 2017-12-20 2022-11-22 University Health Network System, methods, and devices for calculating hypoxic fraction and equilibration rate of small molecular weight tracers using dynamic imaging
CN118076359A (zh) 2021-08-27 2024-05-24 深圳艾欣达伟医药科技有限公司 使用th-302治疗parp抑制剂耐药的患者
CN117651548A (zh) 2021-08-27 2024-03-05 深圳艾欣达伟医药科技有限公司 冻干制剂溶液及冻干制剂、方法和用途
US20250186468A1 (en) 2022-03-15 2025-06-12 Ascentawits Pharmaceuticals, Ltd. Method for treating patient with brca-mutated cancer
CN119384281A (zh) 2022-04-15 2025-01-28 深圳艾欣达伟医药科技有限公司 使用th-302单药或联用parp抑制剂治疗癌症的方法
WO2023226959A1 (zh) 2022-05-23 2023-11-30 深圳艾欣达伟医药科技有限公司 烷化剂前药与细胞周期抑制剂联用治疗癌症的方法
CN119894521A (zh) 2022-09-22 2025-04-25 深圳艾欣达伟医药科技有限公司 乏氧激活的化合物在制备治疗癌症患者的药物中的用途
WO2024179467A1 (zh) * 2023-02-27 2024-09-06 深圳艾欣达伟医药科技有限公司 溶液、冻干制剂、冻干制剂单位包装、注射液及注射液配制方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030091574A1 (en) * 2001-03-23 2003-05-15 Gevas Philip C. Combination treatment of pancreatic cancer
US20070117784A1 (en) * 2005-03-04 2007-05-24 Novacea, Inc. Treatment of hyperproliferative diseases with anthraquinones
JP5765634B2 (ja) * 2008-10-21 2015-08-19 スレッシュホールド ファーマシューティカルズ, インコーポレイテッド 低酸素活性化型プロドラッグを用いるがんの処置
MX2012014416A (es) * 2010-06-28 2013-02-27 Threshold Pharmaceuticals Inc Tratamiento de cancer de sangre.
KR20130045341A (ko) * 2010-07-12 2013-05-03 쓰레솔드 파마슈티컬스, 인코포레이티드 암 치료를 위한 저산소증 활성 프로드러그와 항혈관형성제의 투여
US10357577B2 (en) * 2010-07-16 2019-07-23 Auckland Uniservices Limited Bacterial nitroreductase enzymes and methods relating thereto

Similar Documents

Publication Publication Date Title
JP2016519107A5 (enExample)
ZA202107358B (en) Method for treating alzheimer's disease
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
IN2015DN00450A (enExample)
CY1123501T1 (el) Χρηση ρεσλιζουμαμπης για τη θεραπευτικη αντιμετωπιση μετριου εως σοβαρου ηωσινοφιλικου ασθματος
BR112022002609A2 (pt) Métodos de tratamento de tumores estromais gastrointestinais
PH12017500392A1 (en) Medical treatments based on anamorelin
CN111989095A (zh) 预防或治疗肿瘤疗法副作用的方法
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
NZ754328A (en) Marker for acid sphingomyelinase disorders and uses thereof
JP2013536236A5 (enExample)
IL264407A (en) Novel application of gzd824 and pharmaceutically acceptable salts thereof in treating diseases
UA118474C2 (uk) (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
HUE066609T2 (hu) Adagolási forma betegség kezelésében vagy megelõzésében történõ alkalmazásra
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
Estenkova et al. About the SPA and resort-based treatment of the patients with oncological diseases
JP2019513151A5 (enExample)
Yamada Febrile neutropenia and peripheral nerve injuries: 3 case reports
Yu et al. CLINICAL INVESTIGATION OF THERAPEUTIC EFFECT OF HUO ZHEN AND HERBAL FUMIGANT IN TREATING ARTHRALGIA SYNDROME
Davies Acquired resistance in non-small cell lung cancer: case report
Stepanov et al. Experience of Vasonat usage in treatment of patients with chronic toxic hepatitis
Kilincalp Azathioprine/corticosteroid
CN302191919S (zh) 医用x射线乳腺摄影系统
CN302536694S (zh) 病人用界面组件